Document Detail

Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
MedLine Citation:
PMID:  19956857     Owner:  NLM     Status:  MEDLINE    
To bypass resistance due to limited entry into the cell derivatives of cytarabine (CP-4055, elacytarabine) and gemcitabine (CP-4126) containing a fatty acid chain at the 5' position of the nucleoside were developed. CP-4055 showed an increased retention of the active metabolite, the triphosphate. This characteristic was supposed to favor combinations, such as with the tubulin antagonist docetaxel, the platinum oxaliplatin and the antifolate pemetrexed. The role of the cell cycle effects of CP-4055 and CP-4126 on the efficacy of the combination with docetaxel or pemetrexed was determined. The combination of CP-4055 with oxaliplatin and docetaxel was also evaluated in a mouse xenograft model. CP-4055 induced a G2/M and S phase accumulation and CP-4126 an S phase accumulation. Both analogs induced a dose-dependent cell kill (apoptosis and necrosis). None of the docetaxel combinations induced a synergistic effect. The combination of docetaxel with CP-4055 or CP-4126 induced a G2/M accumulation in the A549 (lung cancer) cell line, but a G0/G1 accumulation in the WiDR (colon cancer) cell line. Preincubation with docetaxel induced an increased cell kill in both cell lines. The combination with oxaliplatin showed a synergistic effect in both cell lines. Combinations with pemetrexed were antagonistic in both cell lines. In the A549 cell line pemetrexed with CP-4055 led to an increase of the G0/G1 phase and the S phase. In WiDR the combination of pemetrexed with CP-4055 increased the G0/G1 phase and increased the cell kill. Pemetrexed with CP-4126 induced an increase in the G0/G1 phase and the S phase in the A549 cell line. In the xenograft study, on a colon cancer and a lung metastasis model, the combination of CP-4055 with docetaxel showed the best results. Treatment with CP-4055 followed by docetaxel after 4 h resulted in a reduction in metastasis in a lung metastasis model, and a favorable toxicity profile was observed. In conclusion, the combinations with oxaliplatin showed a synergistic effect in the combination studies. Although the combinations with docetaxel did not show an enhanced effect in the in vitro studies, this combination revealed an increased effect in the xenograft model.
A D Adema; A C Laan; F Myhren; I Fichtner; H M Verheul; M L Sandvold; G J Peters
Related Documents :
8212067 - Aminoguanidine inhibits cell proliferation by prolongation of the mitotic phase.
11862457 - Lymphoblasts already in the dna synthesis phase of the cell cycle can be reversibly arr...
1750567 - Low salt mimics effects of dark pulses on circadian pacemaker in cultured chick pineal ...
3419447 - Generalized blocking in s phase by methotrexate.
18206227 - Mri characterization of agarose gel micro-droplets at acute time-points within the rabb...
9386987 - Mutants of basic fibroblast growth factor identify different cellular response programs.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of oncology     Volume:  36     ISSN:  1791-2423     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-03     Completed Date:  2010-02-22     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  285-94     Citation Subset:  IM    
Department of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Cell Cycle / drug effects*
Cell Line, Tumor
Chemistry, Pharmaceutical / methods
Cytarabine / analogs & derivatives*,  pharmacology
Deoxycytidine / analogs & derivatives*,  pharmacology
Drug Design
Drug Screening Assays, Antitumor
Fatty Acids / metabolism*
Inhibitory Concentration 50
Neoplasm Metastasis
Neoplasm Transplantation
Organoplatinum Compounds / pharmacology*
Taxoids / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents; 0/CP 4126; 0/Fatty Acids; 0/Organoplatinum Compounds; 0/Taxoids; 101235-34-1/5'-oleoyl cytarabine; 147-94-4/Cytarabine; 15H5577CQD/docetaxel; 63121-00-6/oxaliplatin; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of proteinase inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and tissues.
Next Document:  Anticancer bioactive peptide suppresses human gastric cancer growth through modulation of apoptosis ...